AI assistant
Novartis AG — Director's Dealing 2018
May 11, 2018
940_dirs_2018-05-11_06938d80-f967-4df1-ac59-935c38712c45.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2018-05-09
Reporting Person: Novartis Bioventures Ltd (N/A)
Reporting Person: NOVARTIS AG (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-09 | Common Stock | S | 51230 | $10.11 | Disposed | 2217589 | Direct |
| 2018-05-10 | Common Stock | S | 22725 | $10.13 | Disposed | 2194864 | Direct |
Footnotes
F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.48. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.34. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.